The pharmaceutical giant said Q3 EPS rose 1% to 95 cents, 3 cents above views. Revenue fell 4% to $11.5 bil, under views due to the loss of its patent on Singulair, an asthma and allergy treatment. It affirmed but narrowed its previous full-year EPS guidance, which is now $3.78-$3.82, up a few cents from last year. Merck (MRK) shares fell 0.3% to 46.15.
- Investment & Company Information